What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Her primary scientific interests are in Internal medicine, Breast cancer, Oncology, Cancer and Surgery.
Her work in Clinical trial, Fulvestrant, Metastatic breast cancer, Adjuvant therapy and Chemotherapy is related to Internal medicine.
The concepts of her Breast cancer study are interwoven with issues in Hazard ratio and Pathology.
Her Oncology research includes elements of Complete response, Clinical endpoint, Proportional hazards model and Palbociclib.
Her Palbociclib study integrates concerns from other disciplines, such as Cyclin E, Placebo and Hormone receptor.
Her studies in Cancer integrate themes in fields like Radiology, MEDLINE, Immunology and Family medicine.
Her most cited work include:
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (753 citations)
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer (463 citations)
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer (408 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
Angela DeMichele combines subjects such as Physical therapy, Gynecology and Cancer research with her study of Breast cancer.
Her research in Clinical trial, Palbociclib, Metastatic breast cancer, Trastuzumab and Clinical endpoint are components of Internal medicine.
The Clinical trial study combines topics in areas such as Randomized controlled trial and Disease.
Her Oncology research incorporates themes from Cyclophosphamide, Paclitaxel, MammaPrint, Neutropenia and Biomarker.
Her Cancer study combines topics in areas such as Immunology, Cohort and Bioinformatics.
She most often published in these fields:
- Breast cancer (68.95%)
- Internal medicine (65.53%)
- Oncology (52.99%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (65.53%)
- Breast cancer (68.95%)
- Oncology (52.99%)
In recent papers she was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Neoadjuvant therapy.
Her research integrates issues of MEDLINE and Cardiology in her study of Internal medicine.
Her work deals with themes such as Randomized controlled trial, Clinical trial, Proportional hazards model and Chemotherapy, which intersect with Breast cancer.
Her Chemotherapy research is multidisciplinary, incorporating elements of Stage and De-escalation.
Her Oncology research is multidisciplinary, incorporating perspectives in Pembrolizumab, Adverse effect, Palbociclib, Clinical endpoint and Hazard ratio.
Her Cancer research includes themes of Immunology, Immune system, Neutropenia and Cohort.
Between 2018 and 2021, her most popular works were:
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. (94 citations)
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial (90 citations)
- Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. (23 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Breast cancer, Internal medicine, Oncology, Cancer and Metastatic breast cancer are her primary areas of study.
In the subject of general Breast cancer, her work in Neoadjuvant therapy is often linked to Context, thereby combining diverse domains of study.
Her study in Cardiotoxicity, Biomarker and Proportional hazards model falls under the purview of Internal medicine.
Angela DeMichele has included themes like Cardiomyopathy, Paclitaxel, Clinical endpoint, Hazard ratio and Cardiac dysfunction in her Oncology study.
Her research in Cancer tackles topics such as Cohort which are related to areas like Immune system, Serology, B cell, Immunology and Viral load.
Her work carried out in the field of Metastatic breast cancer brings together such families of science as Letrozole, Cancer research, Tolerability and Cumulative incidence.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
